These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781 [TBL] [Abstract][Full Text] [Related]
26. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS; JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267 [TBL] [Abstract][Full Text] [Related]
27. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585 [TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801 [TBL] [Abstract][Full Text] [Related]
29. Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer. Milà-Alomà M; Salvadó G; Shekari M; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; González-de-Echávarri JM; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Suárez-Calvet M; Molinuevo JL J Prev Alzheimers Dis; 2021; 8(1):68-77. PubMed ID: 33336227 [TBL] [Abstract][Full Text] [Related]
30. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Blennow K; Zetterberg H; Rinne JO; Salloway S; Wei J; Black R; Grundman M; Liu E; Arch Neurol; 2012 Aug; 69(8):1002-10. PubMed ID: 22473769 [TBL] [Abstract][Full Text] [Related]
31. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Touchon J; Perret-Liaudet A; Lehmann S Brain Res; 2010 Oct; 1357():175-83. PubMed ID: 20713025 [TBL] [Abstract][Full Text] [Related]
32. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456 [TBL] [Abstract][Full Text] [Related]
33. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432 [TBL] [Abstract][Full Text] [Related]
34. Relative ratio and level of amyloid-β 42 surrogate in cerebrospinal fluid of familial Alzheimer disease patients with presenilin 1 mutations. Tagami S; Okochi M; Yanagida K; Kodama T; Arai T; Kuwano R; Ikeuchi T; Takeda M Neurodegener Dis; 2014; 13(2-3):166-70. PubMed ID: 24192669 [TBL] [Abstract][Full Text] [Related]